Arcus Biosciences (RCUS) Cash from Investing Activities (2017 - 2026)

Arcus Biosciences' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at $114.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 256.25% year-over-year to $114.0 million; the TTM figure through Mar 2026 stood at $148.0 million (up 26.5% YoY), while the FY2025 annual figure was $66.0 million, up 178.57% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $114.0 million, up from -$182.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $137.0 million in Q2 2025, with the low at -$268.0 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is $28.0 million (2023), against an average of -$7.2 million.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities sank 7259.51% in 2022, then soared 372.41% in 2025.
• Arcus Biosciences' Cash from Investing Activities stood at $47.0 million in 2022, then slumped by 40.43% to $28.0 million in 2023, then soared by 82.14% to $51.0 million in 2024, then tumbled by 456.86% to -$182.0 million in 2025, then soared by 162.64% to $114.0 million in 2026.
• Business Quant data shows RCUS's Cash from Investing Activities at $114.0 million in Q1 2026, -$182.0 million in Q4 2025, and $79.0 million in Q3 2025.